RLAY Relay Therapeutics, Inc.

8-K Current Report

Filed: March 11, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc. (RLAY) 8-K current report filed with SEC EDGAR on March 11, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 5.03: Amendments to Articles of Incorporation or Bylaws

AI Filing Analysis
8-K

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

• Bylaws amended March 6, 2026 to require all Securities Act/Exchange Act claims be filed in federal district court only
• Exclusive federal forum clause limits shareholders' ability to bring securities litigation in state courts

+1 more insights

Other Relay Therapeutics, Inc. 8-K Filings

8-K Mar 16, 2026

8-K Feb 26, 2026

Get deeper insights on Relay Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.